Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing
NCT06406114Phase 2Recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- May 2025
- Primary completion
- Jul 2028
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cephalosporin allergy (2 arms), sponsored by Massachusetts General Hospital. Primary endpoints: Proportion of participants with confirmed culprit cephalosporin allergy at 7 weeks, Cephalosporin skin test sensitivity and specificity at 7 weeks and 1 more. Started May 2025; status: recruiting.
02
Conditions
cephalosporin allergy
Beyond the preview
Go deeper on NCT06406114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06406114.